News Headlines Article

High court weighs drug firms’ generics policy
Modern Healthcare

The U.S. Supreme Court struggled Monday with whether it should allow federal officials to challenge deals between pharmaceutical corporations and their generic drug competitors that the government says could keep cheaper forms of medicine off the American market for longer periods of time.

Justices heard arguments from the Justice Department against what they call “pay-for-delay” deals or “reverse settlements.”